🏅 FDA Orphan Designation

Fyarro

sirolimus protein-bound particles for injectable suspension (albumin-bound)

Manufacturer: Aadi Bioscience, Inc.

Indicated for:

Perivascular epithelioid cell neoplasmOrphan

FDA-Approved Indications (1)

Perivascular epithelioid cell neoplasmOrphan Designation

treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

Indications & Usage

1 INDICATIONS AND USAGE FYARRO ™ is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). ( 1 )

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.